Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lonza sees no delays for COVID-19 vaccine project, citing Trump backing

share with twitter share with LinkedIn share with facebook
07/24/2020 | 03:23am EDT
FILE PHOTO: Logo of Swiss pharmaceutical group Lonza is seen in Basel

Swiss drugmaker Lonza sees no delays for its project to make Moderna's COVID-19 vaccine candidate and has "strong support" from U.S. President Donald Trump to get the necessary manufacturing equipment, its chairman said.

Chairman Albert Baehny had earlier raised concerns that hiring qualified staff and finding gear like bioreactors on short notice could snarl aggressive goals to begin commercial manufacturing of vaccine ingredients for Moderna.

Lonza is readying production of smaller batches this month for Moderna's mRNA vaccine trials in 30,000 people.

Baehny told reporters he remains confident he will find workers and the equipment he needs to complete commercial manufacturing facilities this year in Portsmouth, New Hampshire, and early next year in Visp, Switzerland.

"We are doing very well having access to the people, we can build up the teams in Portsmouth and in Visp to manufacture in the future these drug substances," he said.

"There are basically no major issues in equipment, it's a bit more complicated than the people, but I don't think we'll be facing delays because of delays in equipment delivery, as we see it today," he said. "We have strong support from the Trump administration to have access to the equipment, as well."

Baehny made the comments as Lonza reported a rise in first-half sales and profit and unveiled plans to begin selling its speciality ingredients unit in the second half of 2020.

Lonza is exiting chemicals to focus on its faster-growing drugs business that has a 10-year deal with Moderna to make ingredients for its drugs, including the vaccine candidate.

First-half profit rose 22% to 478 million Swiss francs (406.08 million pounds) on increasing demand from biotech customers. Sales rose 3.3% to 3.1 billion francs, matching consensus estimates.

(Reporting by John Miller; Editing by John Revill, Stephen Coates and Emelia Sithole-Matarise)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
GEBERIT AG -0.62% 545.4 Delayed Quote.1.03%
LONZA GROUP AG -2.68% 582 Delayed Quote.69.31%
MODERNA, INC. -2.54% 72.15 Delayed Quote.278.02%
share with twitter share with LinkedIn share with facebook
All news about MODERNA, INC.
07:23aLabCorp launches test to measure COVID-19 antibodies in clinical trials
10/16Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November
10/16Health Care Up As Pfizer Lays Out Possible Vaccine Timeline -- Health Care Ro..
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
10/16Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November -- ..
10/16Look Who's Really Chasing Hot Stocks Like Zoom
10/16MODERNA : to Report Third Quarter 2020 Financial Results on Thursday, October 29..
10/16Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November -- ..
10/16Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November -- ..
10/16Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November -- ..
More news
Financials (USD)
Sales 2020 305 M - -
Net income 2020 -537 M - -
Net cash 2020 2 553 M - -
P/E ratio 2020 -51,9x
Yield 2020 -
Capitalization 29 176 M 29 176 M -
EV / Sales 2020 87,3x
EV / Sales 2021 5,24x
Nbr of Employees 975
Free-Float 89,8%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 91,47 $
Last Close Price 73,94 $
Spread / Highest target 83,9%
Spread / Average Target 23,7%
Spread / Lowest Target -44,5%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.278.02%29 176
LONZA GROUP AG69.31%48 545
SEAGEN INC.75.85%34 961
CELLTRION, INC.41.16%30 032
IMMUNOMEDICS, INC.313.80%20 254